{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:19:38Z","timestamp":1784819978905,"version":"3.55.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamadermatol.2020.2158","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:02:59Z","timestamp":1595415779000},"page":"1107","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase\u20134 Inhibitor vs Second-generation Sulfonylurea"],"prefix":"10.1001","volume":"156","author":[{"given":"Hemin","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajinkya","family":"Pawar","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi200042r1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"issue":"2","key":"doi200042r2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2337\/dci16-0035","article-title":"DPP-4 inhibitor\u2013related pancreatitis: rare but real!","volume":"40","author":"DeVries","year":"2017","journal-title":"Diabetes Care"},{"issue":"7","key":"doi200042r3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.312673","article-title":"Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? clues from laboratory models and clinical trials.","volume":"122","author":"Packer","year":"2018","journal-title":"Circ Res"},{"issue":"5","key":"doi200042r4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40264-016-0399-8","article-title":"Dipeptidyl peptidase (DPP)-4 inhibitor\u2013induced arthritis\/arthralgia: a review of clinical cases.","volume":"39","author":"Mascolo","year":"2016","journal-title":"Drug Saf"},{"issue":"13","key":"doi200042r6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/archinternmed.2010.188","article-title":"Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.","volume":"170","author":"Desai","year":"2010","journal-title":"Arch Intern Med"},{"issue":"suppl 2","key":"doi200042r7","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.2337\/dc11-s229","article-title":"DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.","volume":"34","author":"Dicker","year":"2011","journal-title":"Diabetes Care"},{"issue":"9863","key":"doi200042r8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases.","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"doi200042r9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jdv.2012.26.issue-2","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi200042r10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi200042r11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"doi200042r12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes.","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"7","key":"doi200042r13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study.","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi200042r14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland.","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi200042r15","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients.","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi200042r16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480498","article-title":"Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid.","volume":"233","author":"Schaffer","year":"2017","journal-title":"Dermatology"},{"issue":"12","key":"doi200042r17","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies.","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"8","key":"doi200042r18","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes.","volume":"42","author":"Douros","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"doi200042r19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the US: real-world evidence in patients newly diagnosed with type 2 diabetes.","volume":"41","author":"Montvida","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"doi200042r20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"25","key":"doi200042r21","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"7662","key":"doi200042r22","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study.","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"doi200042r23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00403-017-1778-4","article-title":"Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients.","volume":"309","author":"Thorslund","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"doi200042r24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial.","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"doi200042r25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/14740338.2019.1668373","article-title":"Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic\/pharmacokinetic assessment through an analysis of the Vigibase\u00ae.","volume":"18","author":"Carnovale","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"doi200042r26","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor\u2013associated bullous pemphigoid.","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"doi200042r27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ehjcvp\/pvv044","article-title":"Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.","volume":"2","author":"Remm","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"doi200042r28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.tips.2009.08.003","article-title":"Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?","volume":"30","author":"Yazbeck","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"doi200042r29","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid.","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi200042r30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo.","volume":"181","author":"Forssmann","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"doi200042r31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population.","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi200042r32","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A basic study design for expedited safety signal evaluation based on electronic healthcare data.","volume":"19","author":"Schneeweiss","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"doi200042r33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies.","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"doi200042r34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch Dermatol"},{"issue":"4","key":"doi200042r35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176209","article-title":"Increase in serum albumin concentration is associated with prediabetes development and progression to overt diabetes independently of metabolic syndrome.","volume":"12","author":"Jun","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"doi200042r36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/bjd.14172","article-title":"Validation of database search strategies for the epidemiological study of pemphigus and pemphigoid.","volume":"174","author":"Hsu","year":"2016","journal-title":"Br J Dermatol"},{"key":"doi200042r5","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Published August 28, 2015. Accessed September 29, 2019. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2768558\/jamadermatology_lee_2020_oi_200042_1602515670.16933.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T11:49:17Z","timestamp":1602676157000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2768558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.2158","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}